Patent ID: 9642888
Date: 2017-05-09
CPC Classifications: A61K,A61P

Claim:
1. A method for treating interstitial lung disease or pulmonary fibrosis characterized by aberrant fibroblast proliferation and extracellular matrix deposition in a lung tissue of a subject in need thereof, the method comprising: administering to the subject a pharmaceutical composition comprising a therapeutic amount of a polypeptide of the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof, selected from the group consisting of a polypeptide of amino acid sequence FAKLAARLYRKALARQLGVAA (SEQ ID NO: 3); a polypeptide of amino acid sequence KAFAKLAARLYRKALARQLGVAA (SEQ ID NO: 4); and a polypeptide of amino acid sequence HRRIKAWLKKIKALARQLGVAA (SEQ ID NO: 7), and a pharmaceutically acceptable carrier thereof, wherein the therapeutic amount is effective to reduce one or more of (i) development of fibrotic loci in the lung tissue; (ii) collagen accumulation in the lung tissue; or (iii) progression of collagen deposition in the lung tissue, compared to a control vehicle.